子宫内膜癌孕激素耐药的非孕激素受体机制研究进展  

Research Progress in Non-progesterone Receptor Mechanism of Progesterone Resistance of Endometrial Carcinoma

作　　者：安琪 王轶英[2] AN Qi;WANG Yiying(Xinxiang Medical University,Xinxiang 453000,China;Department of Gynecology and Obstetrics,People′s Hospital of Henan Province,Zhengzhou 450003,China)

机构地区：[1]新乡医学院,河南新乡453000 [2]河南省人民医院妇产科,郑州450003

出　　处：《医学综述》2023年第12期2306-2310,共5页Medical Recapitulate

基　　金：国家自然科学基金(81972441)。

摘　　要：部分采取保守治疗的子宫内膜增生及子宫内膜癌患者对孕激素治疗表现出低反应或无反应,若能在治疗前筛查出这部分患者,实现精准诊疗,则可在一定程度上减少不良预后的发生。既往孕激素耐药相关研究多局限于孕激素受体本身,无法解释受体缺乏患者对孕激素治疗仍有效这一现象。孕激素主要通过孕激素核受体经典通路和非基因组途径发挥作用。因此,未来深入研究非孕激素受体在子宫内膜癌中的作用机制,可为逆转子宫内膜癌孕激素耐药提供新的治疗靶点。Some patients with endometrial hyperplasia and endometrial carcinoma treated conservatively show low response or no response to progesterone treatment.If these patients can be screened out before treatment to achieve accurate diagnosis and treatment,the occurrence of poor prognosis will be partly reduced.Previous studies related to progesterone resistance were mostly limited to the progesterone receptor,but could not explain the phenomenon that progesterone treatment was still effective for some patients without the receptors.Progesterone acts mainly through the classical and nongenomic pathway of progesterone nuclear receptor.Therefore,future in-depth investigation of the mechanism of non-progesterone receptors in endometrial cancer could provide new therapeutic targets for the reversal of progesterone resistance in endometrial cancer.

关 键 词：子宫内膜癌 孕激素耐药 非孕激素受体 子宫内膜增生 保留生育力 

分 类 号：R737.33[医药卫生—肿瘤]